Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
persistent or recurrent ovarian epithelial or primary peritoneal cancer. Imatinib mesylate
may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth